Statement Of Cash Flows [Abstract]

ABIVAX - Filing #5984181

Concept	2024-01-01 to 2024-12-31	As at 2024-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Cash flows from (used in) operating activities	154 072 EUR	—	97 130 EUR	—	—	53 936 EUR	—
Cash flows from (used in) investing activities [abstract]
Purchase of property, plant and equipment, classified as investing activities	640,000 EUR	—	265,000 EUR	—	—	288,000 EUR	—
Purchase of intangible assets, classified as investing activities	3,000 EUR	—	— EUR	—	—	35,000 EUR	—
Purchase of other long-term assets, classified as investing activities	— EUR	—	— EUR	—	—	2 913 EUR	—
Interest received, classified as investing activities	8 178 EUR	—	2 400 EUR	—	—	19,000 EUR	—
Cash flows from (used in) investing activities	15 762 EUR	—	8 095 EUR	—	—	12 026 EUR	—
Cash flows from (used in) financing activities [abstract]
Payments of lease liabilities, classified as financing activities	458,000 EUR	—	529,000 EUR	—	—	301,000 EUR	—
Interest paid, classified as financing activities	7 696 EUR	—	5 279 EUR	—	—	4 015 EUR	—
Other inflows (outflows) of cash, classified as financing activities	245,000 EUR	—	163,000 EUR	—	—	3,000 EUR	—
Cash flows from (used in) financing activities	28 207 EUR	—	335 290 EUR	—	—	32 211 EUR	—
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents	2 382 EUR	—	5 072 EUR	—	—	— EUR	—
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes	107 720 EUR	—	224 992 EUR	—	—	33 751 EUR	—
Cash and cash equivalents	—	144 221 EUR	—	251 942 EUR	26 950 EUR	—	60 701 EUR